Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescenceLimitations of the complement-fixation test for distinguishing naturally acquired from vaccine-induced yellow fever infection in flavivirus-hyperendemic areasThe 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. 3. Serological responses in persons with and without pre-existing heterologous group B immunityA Recombinant Vesicular Stomatitis Virus Ebola Vaccine — Preliminary ReportParenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infectionLassa fever: review of epidemiology and epizootiologyReplication of Colorado tick fever virus within human hematopoietic progenitor cellsYellow Fever: 100 Years of DiscoveryThe 1970 yellow fever epidemic in Okwoga District Benue Plateau State, Nigeria. 2. Immunity survey to determine geographic limits and origins of the epidemicArbovirus studies in Nupeko forest, a possible natural focus of yellow fever virus in Nigeria. I. Description of the area and serological survey of humans and other vertebrate hostsDengue virus infections in Nigeria: a survey for antibodies in monkeys and humansYellow Fever Remains a Potential Threat to Public HealthFever versus fever: the role of host and vector susceptibility and interspecific competition in shaping the current and future distributions of the sylvatic cycles of dengue virus and yellow fever virusInvestigation of a possible yellow fever epidemic and serosurvey for flavivirus infections in northern Cameroon, 1984Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primatesMolecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.Single mutation in the flavivirus envelope protein hinge region increases neurovirulence for mice and monkeys but decreases viscerotropism for monkeys: relevance to development and safety testing of live, attenuated vaccines.Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccineRecent isolations of Lassa virus from Nigerian rodentsArthropod-borne encephalitides in the AmericasPersistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccineThe 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. I. Epidemiological observationsProtection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1The effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinationsUse of a Surrogate Chimeric Virus To Detect West Nile Virus-Neutralizing Antibodies in Avian and Equine SeraDoes Restricted Distribution Limit Access and Coverage of Yellow Fever Vaccine in the United States?Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimensEvaluation of Chimeric Japanese Encephalitis and Dengue Viruses for Use in Diagnostic Plaque Reduction Neutralization TestsImmunoglobulin M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis encephalitisEfficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster modelEpidemic arboviral diseases: priorities for research and public healthChimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitisSynthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochlorideAntiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substancesDengue: the risk to developed and developing countriesACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice.Japanese encephalitis vaccines: current vaccines and future prospects.
P50
Q22330835-4152794C-6B3D-4F84-84CB-28B3FF87643DQ22330870-C41C4B24-2511-4A3C-991A-A760CC0540E2Q22330872-4A07CACF-B3D4-43A6-9D8A-7379875D2DF4Q24289295-D9127175-4173-4027-B3B6-EB41FD6C4C13Q24548763-76B9AE58-58B2-4E19-9AD4-B78412E134CDQ24647130-AC053502-006A-49D2-B049-C5B285281C6EQ24647911-7D34B77E-3154-4002-A97F-FF422D450058Q24657365-DCBC1974-7EF2-4E5C-A4B6-09E7454B4429Q24696035-690BE935-9813-4686-B63E-02027EABA98AQ24696037-C0FC7866-9DA9-4BF0-93FC-8ADB4B23398DQ24696039-DCD61F31-BDD1-478A-AA48-0937E755DF1AQ26247175-1D34B144-2286-429B-BE9D-CF152513A1CFQ26864533-761EF17D-0B0D-4546-96E9-8470EB536DF4Q27469195-E965BC98-352B-4E0A-8E94-562B225E02B4Q27469631-F3F48AE3-7F52-4829-9710-ABB123A1E9A9Q27469664-A847DD1C-A25E-4CD2-8A66-BD8259DBA689Q27469763-6AB8A66F-84FE-4945-AFE5-44F9DA169AC5Q27469921-2B3DD90F-4454-4A0D-A32E-B104F15333E4Q27472841-E70438D8-072D-41A6-BA65-86B4D1D18B9FQ27477782-211138D2-88AB-407B-9F82-E4DA00AA672AQ27485971-B0FD1A27-73C4-4213-A71F-E95AC9AC9615Q27486137-B63989CC-2FB9-411A-AA83-ABA91FA63450Q27486149-D57C08FD-DC2E-4C03-A3FF-E9844F703D54Q27486513-02C270FA-379B-4B9A-81A8-1A9607586B6CQ27486827-9516DE35-EA94-4AB4-AE88-0E099DFE5FA0Q27486858-0712A0C8-1871-4762-8723-02F4FBEA6161Q27487560-55E26907-D3E7-4BAA-B0C7-7D29B6414141Q27487903-6AD1D3B1-03F3-4A58-9441-FB0A87078699Q27488417-25E56D0A-E85F-407C-AAC6-413FA30DF421Q27488878-4A94978C-D6A8-443C-B009-700D7AC7C877Q27488947-806A950D-C412-4068-A113-6B162E079E34Q27489554-E7FA36A6-9C7A-48B4-97A6-EDD321ECEBE8Q28119368-F997665C-DF4A-4041-A992-33B135AFB396Q28237906-5069C713-286C-4D74-9425-B1B898D85D49Q28318433-F28C7AA5-7707-40BE-B45D-07DBAD0857B5Q28327151-EB0AFCDF-240E-431F-967A-F6FDEF11426FQ29619739-6BC2BA76-A80A-4A3F-88F6-77EB21283FA7Q30233182-B1F94A52-1CC2-4357-8866-A8E043F41F57Q30409505-B1CD883E-E313-4FC9-BB3F-1261611CE895Q31087320-710E8B3D-2482-4407-9B72-DD5FA06BA709
P50
description
American physician, virologist and vaccine developer
@en
wetenschapper
@nl
name
Thomas P. Monath
@ast
Thomas P. Monath
@en
Thomas P. Monath
@nl
type
label
Thomas P. Monath
@ast
Thomas P. Monath
@en
Thomas P. Monath
@nl
prefLabel
Thomas P. Monath
@ast
Thomas P. Monath
@en
Thomas P. Monath
@nl
P1006
P214
P244
P1006
P106
P21
P214
P244
P31
P496
0000-0001-7509-4599
P735
P7859
lccn-n80154924